Trial reportObesity (Silver Spring, Md.)2010
Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program.
Trial report in Obesity (Silver Spring, Md.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review.Frontiers in endocrinology · 2020Pooled it
- Metformin and/or clomiphene do not adversely affect liver or renal function in women with polycystic ovary syndrome.The Journal of clinical endocrinology and metabolism · 2011Pooled it
- Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?Cardiovascular diabetology · 2012Trial
- Metformin: Beyond Type 2 Diabetes Mellitus.Cureus · 2024Review
- Metformin and the Liver: Unlocking the Full Therapeutic Potential.Metabolites · 2024Review
- PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: A network meta-analysis.The Journal of international medical research · 2023Article
- In Vitro and In Ovo Evaluation of the Potential Hepatoprotective Effect of Metformin.Medicina (Kaunas, Lithuania) · 2022Article
- A Clinical Perspective of the Multifaceted Mechanism of Metformin in Diabetes, Infections, Cognitive Dysfunction, and Cancer.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Pentoxifylline with metformin treatment improves biochemical parameters in patients with nonalcoholic steatohepatitis.Journal of medical biochemistry · 2020Article
- Effect ofDiabetes, metabolic syndrome and obesity : targets and therapy · 2020Article
- Article
- A Polygenic Lipodystrophy Genetic Risk Score Characterizes Risk Independent of BMI in the Diabetes Prevention Program.Journal of the Endocrine Society · 2019Article
- Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?Pharmaceuticals (Basel, Switzerland) · 2018Review
- Combining metformin therapy with caloric restriction for the management of type 2 diabetes and nonalcoholic fatty liver disease in obese rats.Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme · 2015Article
- Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention.Drugs · 2015 · on this mapReview
- Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns.Archives of medical science : AMS · 2015Article
- Combination Therapy of Metformin and Statin May Decrease Hepatocellular Carcinoma Among Diabetic Patients in Asia.Medicine · 2015Article
- Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.World journal of gastroenterology · 2014Review
- Combining metformin and aerobic exercise training in the treatment of type 2 diabetes and NAFLD in OLETF rats.American journal of physiology. Endocrinology and metabolism · 2014Article
- Lifestyle interventions for the treatment of non-alcoholic fatty liver disease.Hepatic medicine : evidence and research · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
Abstract
Nonalcoholic fatty liver disease (NAFLD) is associated with obesity, insulin resistance, and impaired glucose tolerance. We investigated whether metformin or changes in metabolic measurements (weight, fasting plasma glucose (FPG), or fasting insulin (FI)) improved serum alanine aminotransferase (ALT) activity, as a marker for NAFLD, in the Diabetes Prevention Program (DPP). From 1996 to 1999, 2,153 participants without marked elevations of serum ALT at baseline were randomized (1,081 to placebo, 1,072 to metformin) and treated for an average of 3.2 years. ALT increased during the first 2 years of the study, and was slightly but significantly lower in the participants randomized to metformin. In regression models adjusted for sex, baseline age, FPG, and FI, these differences remained significant, but disappeared after adjustment for weight, FPG, and FI changes at each examination. The 3-year cumulative incidence for development of abnormal ALT concentrations was not significantly different ((mean +/- s.e.) 21.4 +/- 1.4% and 24.6 +/- 1.4%, P = 0.11) in the metformin vs. placebo groups but was lower in individuals in both groups that lost more weight by the end of year 1 (metformin: 19.4 +/- 2.4% vs. 27.5 +/- 3.7%, for highest vs. lowest quartile of weight loss; placebo: 18.7 +/- 3.4% vs. 28.8 +/- 2.6%). Over 3 years of follow-up in persons at high risk for development of diabetes, serum ALT was consistently lower in those treated with metformin compared with placebo. This effect was mediated by weight loss, indicating that the effects of metformin therapy on ALT is via its effects on weight.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.